QV Bioelectronics secures £4.5m in funding for brain cancer therapy development
Esme Needham | February 3, 2026 | News story | Research and Development | Oncology, QV Bioelectronics, glioblastoma
QV Bioelectronics, a medtech business specialising in implants for cancer treatment, has announced that it has received £4.5m in funding to drive innovation in brain cancer.
QV has created an implantable device – the first of its kind globally – designed to improve outcomes in hard-to-treat glioblastoma (GBM). QV’s implant technology is known as Glioma Resection Advanced Cavity Electric Field (GRACE) therapy and uses electric fields to destroy residual brain cancer cells after brain tumour surgery. It was developed by QV founders Dr Christopher Bullock and Dr Richard Fu.
GBM is an aggressive form of cancer that affects around 2,200 adults in the UK annually. Cancer Research UK estimates that GBM accounts for 32% of brain tumours diagnosed in England between 1995 and 2017. Prognosis for the disease is poor: 3% of diagnosed patients live for five years following diagnosis, and less than 1% live for 15 years.
The current average post-diagnosis survival time for GBM-diagnosed patients, according to The Brain Tumour Charity, is between 12 and 18 months.
The goal of QV’s GRACE therapy is to maintain quality of life for GBM patients undergoing treatment, as well as to increase overall survival. Testing performed to date has shown positive results. QV plans to use the new funding to advance the implantable device into clinical trials, with a first-in-human trial planned this year.
Dr Christopher Bullock, co-founder and CEO of QV, said: “Our mission at QV Bioelectronics is simple but ambitious: to develop technology that can meaningfully extend life and give people more time with those they love. This investment allows us to take a major step towards that goal.”
Related Content
Tracon shares data from phase 2 trial for glioblastoma treatment
Tracon Pharmaceuticals has announced the publication of its phase 2 clinical data for its DNA …
FDA grants ODD to ABM Therapeutics’ treatment for patients with glioblastoma
ABM Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan …
Scorpion venom added to CAR-T therapy increases efficacy in brain cancer, research shows
Chimeric antigen receptor T cell (CAR-T) therapy has gained much traction and attention in the …
